Every Form 4 that Nephros Inc. (NEPH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NEPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NEPH filings page.
NEPHROS INC (NEPH) had insider activity reported by entities associated with Wexford Capital LP. On 2026-08-18, Wexford Capital exercised stock options to purchase 3,765 shares of common stock at an exercise price of $3.60 per share through a cashless exercise, with a portion of the option shares withheld to satisfy the exercise price. This resulted in the acquisition of 812 shares of common stock, bringing Wexford Capital’s direct common stock holdings to 56,872 shares and leaving 36,198 stock options outstanding, expiring on August 24, 2026. Wexford GP LLC, Charles E. Davidson and Joseph M. Jacobs may be deemed controlling persons of Wexford Capital and disclaim beneficial ownership except to the extent of any pecuniary interests. The transactions were not reported as made under a Rule 10b5-1 trading plan.
Nephros Inc. director Arthur H. Amron received 2,418 shares of Common Stock on 2026-08-12 as a grant in lieu of cash fees for board service, bringing his direct Common Stock holdings to 140,874 shares. He also holds stock options to acquire 7,323 shares of Common Stock at an exercise price of $2.14 per share that are fully vested, and additional options for 7,050 shares at an exercise price of $1.47 per share that vest in three equal installments of 2,350 shares on 1/1/25, 1/1/26 and 1/1/27.
Nephros Inc. director Arthur H. Amron reported an equity grant of 3,574 shares of Common Stock, issued in lieu of cash fees for board service. The shares were granted at no cash cost, bringing his direct Common Stock holdings to 138,456 shares after the transaction.
He also reports outstanding stock options to purchase 7,050 shares of Common Stock at an exercise price of $1.47 per share expiring on January 1, 2035, and options on 7,323 shares at $2.14 per share expiring on May 14, 2034. Footnotes indicate these options vest in equal annual installments on specified future dates.
Nephros Inc. President and CEO Robert R. Banks Jr. exercised stock options to acquire 120,000 shares of common stock at $1.44 per share on March 23, 2026. Following the transaction, he directly holds 190,000 common shares and retains a remaining option position tied to 10,406 underlying shares expiring in 2034.
Nephros Inc. Chief Financial Officer Judy Krandel exercised stock options to acquire 68,861 shares of common stock at an exercise price of $1.71 per share. The options were previously granted compensation awards. Following the transaction, she directly holds 68,861 common shares.
She also continues to hold stock options over 54,359 shares at an exercise price of $1.68 per share, expiring on March 27, 2035, and options over 4,000 shares at an exercise price of $2.92 per share, expiring on March 16, 2036. Footnotes describe future vesting schedules for these remaining option grants. No open-market purchases or sales were reported in this filing.
Nephros director Arthur H. Amron received a grant of 3,610 shares of Nephros common stock on March 16, 2026, issued in lieu of cash fees for board service. The grant was recorded at a price of $0.00 per share and brings his directly held common stock to 134,882 shares.
He also holds stock options to purchase 7,323 shares at an exercise price of $2.14 per share expiring on May 14, 2034, and options for 7,050 shares at $1.47 per share expiring on January 1, 2035. These options vest in equal annual installments over three years, as described in the filing footnotes.
Nephros Inc.’s Chief Financial Officer Judy Krandel received a stock option grant as part of her compensation. On March 16, 2026, she was granted options to buy 4,000 shares of common stock at an exercise price of $2.92 per share, expiring on March 16, 2036. According to the vesting terms, 1,000 of these options vest on March 16, 2027, and the remaining 3,000 vest in 12 quarterly installments starting on June 16, 2027.
In addition to this new grant, she holds previously awarded options with exercise prices of $1.71 and $1.68 per share that expire in 2033 and 2035, respectively, covering 122,524 and 54,359 underlying shares of common stock. The filing shows only acquisitions and holdings, with no reported sales or dispositions in this report.
Nephros (NEPH) Form 4: A director reported acquiring 1,622 shares of common stock on 11/10/2025 at $0, held directly following the transaction.
The reporting person also holds a stock option to buy 13,229 shares at $4.49, expiring 08/11/2035. The option vests as to 4,410 shares on 6/16/25, 4,410 shares on 6/16/26, and 4,409 shares on 6/16/27.
Nephros, Inc. (NEPH) filed a Form 4 showing insider activity. A director reported acquiring 8,036 shares of common stock on 11/10/2025 at $0, bringing direct beneficial ownership to 122,881 shares following the transaction. The filing also lists multiple outstanding stock options with various exercise prices and expirations, with examples including options exercisable at $5.5755 expiring 08/10/2028 and at $2.14 expiring 05/14/2034.
Nephros (NEPH) Form 4: A director reported acquiring 5,391 shares of common stock on 11/10/2025 at a price of $0. Following this transaction, the director beneficially owned 131,272 shares directly.
The filing also lists outstanding stock options: 7,323 options with a $2.14 exercise price expiring 05/14/2034 and 7,050 options with a $1.47 exercise price expiring 01/01/2035. The vesting schedules include 2,441 shares on each of 5/14/24, 5/14/25, and 5/14/26 for the first grant, and 2,350 shares on each of 1/1/25, 1/1/26, and 1/1/27 for the second.